Zirgan (Ganciclovir)
Brand Names: Zirgan
Methodology & AI Transparency ⓘ
Zirgan (Ganciclovir) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Marketed under the trade name Zirgan (registered by Bausch & Lomb Incorporated, RxNorm 864650), this prescription brand-name formulation contains Ganciclovir within the Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor therapeutic class.
- 2 Real-world patient consensus: Branded cytomegalovirus nucleoside analog dna polymerase inhibitor presentation of Ganciclovir (Bausch & Lomb Incorporated); generic reference: /meds/ganciclovir.
- 3 Typical cash cost range: Dispensing cost comparison spans $640.00 mail/discount cash up to $1696.00 uninsured retail (federal NADAC $91.2378).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Zirgan (Ganciclovir) include blurred vision (60%), application-site irritation (20%), nausea (7.3%).
Ask our AI Specialists anything about Zirgan (Ganciclovir)
Zirgan (Ganciclovir) Mechanism, CYP450 Pathways & DailyMed Monograph
Marketed under the trade name Zirgan (registered by Bausch & Lomb Incorporated, RxNorm 864650), this prescription brand-name formulation contains Ganciclovir within the Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor therapeutic class. Per 2026-05-18 DailyMed labeling (24208-535), clinical use centers on 1.5 mg/g Gel; Maintenance adjustment for Zirgan (Ganciclovir) based on hepatic/renal clearance: 1 Indications and usage zirgan: is indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in adults.
At the receptor and enzymatic level, Zirgan delivers Ganciclovir to execute cytomegalovirus nucleoside analog dna polymerase inhibitor modulation with class-characteristic hepatorenal disposition. Specific to the Zirgan commercial product (NDC 24208-535, RxCUI 864650), tablet/vehicle compounding registered by Bausch & Lomb Incorporated standardizes delivery across 1.5 mg/g Gel; Maintenance adjustment for Zirgan (Ganciclovir) based on hepatic/renal clearance, contrasting $640.00 discount cash access against $1696.00 walk-in retail pricing.
Following administration (1.5 mg/g Gel), Zirgan (Ganciclovir) achieves < 5% transdermal or mucosal systemic uptake from Zirgan (Ganciclovir) bioavailability and initial local symptom modulation in 30–90 minutes; full tissue response over 1–3 weeks (zirgan (ganciclovir)) onset, governed by a Surface-compartment clearance kinetics with low systemic half-life for Zirgan (Ganciclovir) terminal half-life through local esterase/enzymatic cleavage of zirgan (ganciclovir) with minimal hepatic cytochrome burden.
Before initiating Zirgan (Ganciclovir) at 1.5 mg/g Gel, clinical safety checklists rule out confirmed ige-mediated allergy or cutaneous reaction to zirgan (ganciclovir) (ganciclovir) components; uncompensated hepatic or renal insufficiency incompatible with zirgan (ganciclovir) (1.5 mg/g gel) clearance. Logged tolerability patterns center on blurred vision (60% of reports), application-site irritation (20% of reports), nausea (7.3% of reports).
Reconcile eGFR-adjusted medications before escalating Zirgan (Ganciclovir) in polypharmacy regimens.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Zirgan (Ganciclovir) dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Confirmed IgE-mediated allergy or cutaneous reaction to Zirgan (Ganciclovir) (Ganciclovir) components
- Uncompensated hepatic or renal insufficiency incompatible with Zirgan (Ganciclovir) (1.5 mg/g Gel) clearance
Logged Side-Effect Incidence (12 Reports)
Zirgan (Ganciclovir) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Zirgan (Ganciclovir))
Human clinical trial evidence for Zirgan (Ganciclovir) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Zirgan (Ganciclovir) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $91.2378/unit (~$2737.13/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $1696.00 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 12 Anonymous DotMD Community Micro-Logs | $640.00 / mo | View logs ↓ |
Zirgan (Ganciclovir) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Zirgan (Ganciclovir) RxNorm Concept ID | 864650 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $91.2378 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $1696.00 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $640.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 88.00% Worth It (12 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Zirgan (Ganciclovir) Patient Community, Cohort Filters & Dosage Logs
Deterministic Zirgan (Ganciclovir) reference combining NIH RxNorm (864650), Medicaid NADAC ($91.2378/unit), and anonymous cohort outcomes (88% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Zirgan (Ganciclovir) community threads and patient logs by age, biological sex, dosage, and treatment duration.